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Abst rac t
Introduction: Vitiligo is an acquired, idiopathic disorder characterized by circumscribed depigmented macules and 
patches, which affects approximately 0.1–2% of the general population worldwide. Zinc is an essential trace ele-
ment that is necessary for growth and development at all stages of life. Some studies have reported an association 
between serum zinc levels and vitiligo.
Aim: To measure the serum zinc level in patients with vitiligo compared to healthy subjects.
Material and methods: One hundred patients with vitiligo and 100 healthy controls were referred to our clinic. The 
two groups were matched for age and sex. Atomic absorption spectrophotometry was used to measure serum zinc 
levels. The statistical analysis was performed using SPSS software.
Results: The mean serum level of zinc in vitiligo patients and controls was 80.11 ±17.10 µg/dl and 96.10 ±16.16 µg/dl, 
respectively. The serum zinc level in patients with vitiligo was significantly lower than in healthy controls  
(p = 0.0001).
Conclusions: The results of our study revealed a significant association between vitiligo and serum zinc levels. 
A relative decrease in the serum zinc level in vitiligo patients can highlight the role of zinc in the pathogenesis of 
vitiligo, and large-scale studies need to be conducted to confirm these findings and assess the effect of oral zinc 
supplements in patients with low zinc levels.
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Introduction
Vitiligo is an acquired, idiopathic disorder character-
ized by circumscribed depigmented macules and patch-
es, which affects approximately 0.1–2% of the general 
population worldwide [1, 2] and it may appear any time 
from shortly after birth to senescence. The average age 
of onset is variable, but peaks in the second and third de-
cades [3]. The exact pathogenesis of vitiligo is uncertain 
[4]. Vitiligo is a multifactorial disorder related to both ge-
netic and non-genetic factors [5, 6]. It is generally agreed 
that there is an absence of functional melanocytes in the 
vitiligo skin and that this loss of histochemically recog-
nizable melanocytes is a result of their destruction [4, 
7, 8]. There are three basic techniques of genetic stud-
ies: candidate gene association studies, genome-wide 
linkage studies and genome-wide association studies 
(GWAS) [9]. 
The diagnosis of vitiligo is based upon the clinical 
presence of depigmented patches of the skin. Examina-
tion with a Wood’s lamp is useful for highlighting areas 
of pigment loss in lightly-pigmented patients. A full body 
skin examination should be performed in adult patients 
with new-onset vitiligo to exclude a melanoma-associat-
ed depigmentation. Increased frequencies of other auto-
immune disorders, such as autoimmune thyroid disease, 
pernicious anemia, systemic lupus erythematosus, and 
Addison disease have been detected in patients with vit-
iligo [10, 11]. The association of vitiligo with these disor-
ders suggests the presence of shared genetic factors that 
contribute to the development of these diseases.
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Zinc is an essential trace element that is necessary 
for growth and development at all stages of life [12]. Zinc 
plays a key role in physical growth and development, 
functioning of the immune system, reproductive health, 
sensory function and neurobehavioral development. 
It has been estimated that around 33% of the world’s 
human population have diets deficient in zinc, but this 
ranges between 4% and 73% in different countries [13]. 
Mild zinc deficiency is associated with depressed immu-
nity, impaired taste and smell, onset of night blindness, 
and decreased spermatogenesis. Severe zinc deficiency 
is characterized by severely depressed immune function, 
frequent infections, diarrhea, and alopecia [14].
Some investigators have reported an association 
between low serum zinc levels and vitiligo, while others 
have not found the same. 
Aim
This study was conducted to measure the serum zinc 
level in patients with vitiligo and compare it with healthy 
controls.
Material and methods 
Patients and controls
This study was approved by the Ethics Committee of the 
Ardabil University of Medical Sciences. This was a prospec-
tive cross-sectional study. Patients presenting with vitiligo to 
the dermatology outpatient clinic of Imam Khomeini Hospi-
tal in Ardabil, Iran, between March 2012 and April 2013 were 
recruited for the study. A total of 100 patients with acne 
vulgaris and 100 healthy controls were included. The two 
groups were matched for age and sex. The diagnosis of vit-
iligo was based upon the clinical presence of depigmented 
patches of the skin and examination with a Wood’s lamp.
The inclusion criteria for patients with vitiligo were: 
being over 15 years of age, being at least a primary school 
graduate, not taking any medication for any purposes, and 
being willing to participate in the study. Patients were ex-
cluded if they had any disfiguring facial condition other 
than vitiligo, history of active malignancy, under immuno-
suppressive treatment, liver cirrhosis, renal failure, under 
any treatment with zinc in the 1 month prior to diagnosis, 
pregnancy, alcoholism, malabsorption disorders, physical 
disability, any neurological disorder, or other physical dis-
eases, which might cause psychological distress. 
A questionnaire was completed for each patient, 
which included the data of demographic status, medical 
and drug history, duration of vitiligo, and familial status 
for vitiligo. Then, for all participants, laboratory tests 
were recommended, which comprised complete blood 
count, serum calcium, phosphorus and zinc levels, fast-
ing blood sugar, liver function, renal function and thyroid 
function tests, urinalysis and stool examination. Written 
informed consent was obtained from the participants.
Measurement of the serum zinc level
A 3 ml intravenous blood sample was taken from eli-
gible cases and controls, and then taken in a heparinized 
and sterile test tube at –40°C. Blood samples were with-
drawn by zinc-free plastic syringes and placed in zinc-free 
centrifuge tubes. Atomic absorption spectrophotometry 
(Varian Spectra AA-10 Model) was used to measure se-
rum zinc levels. The normal value of the serum zinc level 
in adults was accepted as 70–140 µg/dl.
Statistical analysis
The statistical analysis of the data was done using 
SPSS software (Version 19.SPSS Inc, United States). The 
comparison of the continuous variables was accom-
plished with the Student’s t test, and for the comparison 
of the categorical variables, the c2 test was used. The 
Pearson correlation analysis was used for the evalua-
tion of the correlation between scores of the different 
scales and other relevant variables. A p-value of < 0.05 
was considered statistically significant. The results were 
expressed as means ± standard deviations.
Results
A total of 100 vitiligo patients and 100 healthy volun-
teers were enrolled in this study. Each group included 54 
(54%) men and 46 (46%) women. The mean age of the 
patients was 24.97 ±2.58 years, and the mean age of the 
controls was 25.32 ±2.47 years. The two groups showed 
no significant differences in age or gender. The highest 
prevalence was in the age range of 20 to 29 years (34%).
The mean duration of the disease was 41.37 ±26.41 
months, with a range between 6 and 120 months. Only 
17% of patients had a positive family history. In the vit-
iligo group, 79 (79%) patients were single and 21 (21%) 
patients were married. The mean duration of education 
in this group was 12.39 ±2.85 years. In the control group, 
81 (81%) patients were single and 19 (19%) patients were 
married. The mean duration of education in this group 
was 11.97 ±2.81 years. None of the above demographic 
variables showed any statistically significant differences 
between the vitiligo group and the control group. The 
most common type of vitiligo was the generalized type 
(81%) followed by segmental vitiligo (10%) and focal vit-
iligo (9%). The most common site of involvement was 
found in the lower extremities.
The average serum levels of zinc in vitiligo patients 
and controls are presented in Table 1. The serum zinc 
level in controls ranged from 65 to 120 µg/dl with a mean 
value of 96.10 ±16.16 µg/dl. The serum zinc level in vitili-
go patients ranged from 30.10 to 120 µg/dl, with a mean 
value of 80.11 ±17.10 µg/dl (Table 1). Paired t-test results 
showed that there is a significant difference between the 
zinc serum level in patients with vitiligo compared with 
healthy subjects (p = 0.0001). There was no significant 
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correlation between the serum level of zinc with a family 
history of the disease (p = 0.19), type of vitiligo (p = 0.25), 
and duration of disease (p = 0.25).
Mean serum levels of calcium, phosphorus, fasting 
blood sugar (FBS), and thyroid stimulating hormone 
(TSH) in vitiligo patients and controls are presented in 
Table 2. None of mean serum levels of calcium, phospho-
rus, FBS showed any statistically significant differences 
between the vitiligo group and the control group. Among 
patients with vitiligo, (18) 18% had thyroid dysfunction, 
while in the control group, 9 (9%) had thyroid dysfunc-
tion. There was a significantly higher prevalence of thy-
roid dysfunction in patients with vitiligo compared with 
the control group (p = 0.002). However, there was no sig-
nificant difference in the mean levels of TSH between the 
patient and control group (p = 0.104).
Discussion
Vitiligo is an acquired pigmentary disorder of the skin 
and mucous membranes and is characterized by circum-
scribed, depigmented macules and patches. It commonly 
begins in childhood or young adulthood [15]. The cosmetic 
impact of this disease is tremendous and its psychologi-
cal impact is devastating, particularly in colored races [16].
Theories regarding destruction of melanocytes of vit-
iligo include autoimmune mechanisms, cytotoxic mecha-
nisms, intrinsic melanocyte defects, oxidant-antioxidant 
mechanisms, and neural mechanisms. The autoimmune 
theory proposes an alteration in humoral and cellular im-
munity in the destruction of melanocytes of vitiligo. Au-
toimmune thyroid diseases, particularly Hashimoto thy-
roiditis and Graves disease; other endocrinopathies, such 
as Addison disease and diabetes mellitus; and alopecia 
areata; pernicious anemia; inflammatory bowel disease; 
psoriasis; and autoimmune polyglandular syndromes are 
all associated with vitiligo. This indicates the presence of 
genetically determined susceptibility to not only vitiligo 
but also to other autoimmune disorders [17]. Oxidant 
stress may also play an essential role in the pathogenesis 
of vitiligo. Studies suggest that accumulation of free radi-
cals toxic to melanocytes leads to their destruction [18].
Although the diagnosis of vitiligo generally is made 
on the basis of clinical findings, biopsy is occasionally 
helpful to differentiate vitiligo from other hypopigmen-
tary disorders. Two scores designed for the assessment 
of vitiligo are the vitiligo area severity index (VASI) and 
Vitiligo European Task Force (VETF) [19].
Zinc is a potential antiapoptotic factor. On the other 
hand, based on histological and some laboratory data, 
apoptosis of melanocytes has been suggested as a prob-
able mechanism of vitiligo. Hence, zinc, via preventing 
apoptosis of melanocytes may be able to control vit-
iligo [20]. Zinc in combination with other micronutrients 
plays an important role in the process of melanogenesis. 
They catalyze the rearrangement of dopachrome to from 
5, 6-dihydroxy indole-2-carboxylic acid, and enhancement of 
eumelanin polymer formation from monomers. This process 
is the final stage of eumelanin formation in melanogenesis 
so zinc may have an important effect on vitiligo [21, 22]. 
A number of studies have been made to reveal the ef-
fect of zinc on vitiligo. The present study showed signifi-
cantly lower levels of zinc in serum of patients with vitili-
go compared to the control group (p = 0.0001). Molokhia 
and Portnoy [23] conducted a study to estimate copper 
and zinc levels in serum and skin of vitiligo patients; 
they found a significant reduction in serum zinc, while 
the results of copper analysis in vitiligo neither support 
a deficiency role for copper nor justify its use in the treat-
ment of that disease. Tasaki et al. [24] conducted a study 
to estimate serum copper (Cu) and zinc (Zn) levels and 
copper/zinc ratios in 151 cases of various skin diseases. 
The serum level of Zn was significantly decreased in 
cases of bullous pemphigoid, decubitus ulcer, and alo-
pecia areata. The serum level of Cu was elevated in cases 
of psoriasis, decubitus ulcer, and skin cancer. They also 
demonstrated that, in each skin disease, the Cu/Zn ratio 
clearly reflects the severity of the progress.
Table 2. The mean serum levels of calcium, phosphorus, fasting blood sugar (FBS), and thyroid stimulating hormone 
(TSH) in vitiligo patients and controls
Serum level Vitiligo group (N = 100) Control group (N = 100) P-value
Calcium [mg/dl] 9.3 ±0.49 9.4 ±0.41 0.826
Phosphorus [mg/dl] 3.2 ±0.1 3.4 ±0.2 0.875
FBS [µIU/ml] 86.49 ±11.21 89.68 ±12.48 0.373
TSH [µIU/ml] 2.94 ±4.86 3.19 ±4.69 0.104
Table 1. The mean serum zinc level in vitiligo patients and 
controls
Study subjects Serum zinc [µg/dl] P-value
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Zinc-α2-glycoprotein (ZAG) is a recently identified adi-
pokine, assigned to chromosome 7q22.1. The ZAG plays 
a role in lipolysis, regulation of metabolism, cell prolifera-
tion and differentiation, regulation of melanin synthesis, 
cell adhesion, immunoregulation, and so forth [25]. Zinc 
via precipitating the ZAG in site of vitiligo patches may 
be effective in the treatment of vitiligo [25, 26]. Some 
studies showed a significant increase in the percent-
age of apoptosis in peripheral blood mononuclear cells 
in vitiligo. On the other hand, the accumulation of toxic 
compounds, altered cellular environment and infection 
can all contribute to vitiligo. Zinc may have an effect on 
preventing vitiligo via destructing these probable envi-
ronmental factors through prevention of these immunity-
related cells [20].
In 2014, Zeng et al. [27] conducted a meta-analysis 
to compare the serum levels of Cu and Zn between vit-
iligo patients and healthy controls. In this meta-analysis, 
16 studies with a total of 891 vitiligo cases and 1682 
healthy controls were conducted. The serum levels of 
Cu were significantly lower in vitiligo patients than in 
healthy controls (p < 0.0001). The levels of serum Zn were 
also significantly lower in vitiligo patients than in healthy 
controls (p < 0.00001). These results demonstrated that 
decreased levels of serum Cu and Zn are generally pres-
ent in vitiligo patients [27].
Further investigations with a larger number of pa-
tients and also dividing them into further classifications 
of these diseases to obtain better knowledge of the ef-
fect of zinc are needed. Also, treatment with zinc supple-
ments can be tried in these patients to see the outcome.
Conclusions
The results of our study revealed a significant asso-
ciation between vitiligo and serum zinc levels. A relative 
decrease in the serum zinc level in vitiligo patients can 
highlight the role of zinc in the pathogenesis of vitiligo, 
and large-scale studies need to be conducted to confirm 
these findings and assess the effect of oral zinc supple-
ments in patients with low zinc levels.
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